scispace - formally typeset
E

Edmond J. LaVoie

Researcher at Rutgers University

Publications -  182
Citations -  8160

Edmond J. LaVoie is an academic researcher from Rutgers University. The author has contributed to research in topics: Topoisomerase & Cytotoxicity. The author has an hindex of 42, co-authored 178 publications receiving 7619 citations. Previous affiliations of Edmond J. LaVoie include San Antonio River Authority & National Pingtung University of Science and Technology.

Papers
More filters
Journal ArticleDOI

Bioisosterism: A Rational Approach in Drug Design.

TL;DR: This topic has been reviewed in previous years and the objective of this review is to provide an overview of bioisosteres that incorporates sufficient detail to enable the reader to understand the concepts being delineated.
Journal ArticleDOI

Antioxidative Phenolic Compounds from Sage (Salvia officinalis)

TL;DR: In this article, 10 phenolic compounds were isolated from a butanol fraction of sage extracts and their structures were determined by spectral methods (NMR, MS, IR). Among them, a novel compound, 4-hydroxyacetophenone-4-O-β-d-apiofuranosyl-(1→6)-O- β-dglucopyranoside, was identified.
Journal ArticleDOI

Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity.

TL;DR: Several 2'-aryl-5-substituted-2,5'bi-1H-benzimidazole derivatives were synthesized and evaluated as topoisomerase I poisons and for their cytotoxicity toward the human lymphoblast cell line RPMI 8402.
Journal ArticleDOI

Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation.

TL;DR: It is demonstrated that thiol alkylation of TOP2 can also produce TOP2-mediated DNA damage, suggesting the possibility that cellular DNA damage could occur indirectly through thiolation of a nuclear protein, TOP2.
Journal Article

Identification of Topoisomerase I as the Cytotoxic Target of the Protoberberine Alkaloid Coralyne

TL;DR: It seems possible to develop coralyne and nitidine derivatives as new topo I-targeted therapeutics to overcome aspects of camptothecin-related resistance.